A Rare Adverse Event of Rhabdomyolysis Caused by Sacubitril/Valsartan
Abstract
:1. Introduction
2. Case Narrative
3. Discussion
4. Conclusions
Author Contributions
Funding
Conflicts of Interest
References
- Giannoglou, G.D.; Chatzizisis, Y.S.; Misirli, G. The syndrome of rhabdomyolysis: Pathophysiology and diagnosis. Eur. J. Intern. Med. 2007, 18, 90–100. [Google Scholar] [CrossRef] [PubMed]
- Zutt, R.; van der Kooi, A.J.; Linthorst, G.E.; Wanders, R.J.A.; de Visser, M. Rhabdomyolysis: Review of the literature. Neuromuscul. Disord. 2014, 24, 651–659. [Google Scholar] [CrossRef] [PubMed]
- Torres, P.A.; Helmstetter, J.A.; Kaye, A.M.; Kaye, A.D. Rhabdomyolysis: Pathogenesis, diagnosis, and treatment. Ochsner J. 2015, 15, 58–69. [Google Scholar] [PubMed]
- Melli, G.; Chaudhry, V.; Cornblath, D.R. Rhabdomyolysis. Medicine 2005, 84, 377–385. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Entresto™ [Package Insert]. East Hanover: Novartis Pharmaceuticals Corporation. 2015. Available online: https://www.pharma.us.novartis.com/product/pi/pdf/entresto.pdf (accessed on 18 February 2019).
- Faber, E.S.; Gavini, M.; Ramirez, R.; Sadovsky, R. Rhabdomyolysis After Coadministration of Atorvastatin and Sacubitril/Valsartan (Entresto™) in a 63-Year-Old Woman. Drug Saf. Case Rep. 2016, 3, 14. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Previsdomini, M.; Graziano, E.; Decosterd, L.; Courlet, P.; Perren, A.; Ceschi, A. Severe rosuvastatin accumulation with rhabdomyolysis due to drug interactions and low cardiac output syndrome. Br. J. Clin. Pharmacol. 2019. [Google Scholar] [CrossRef] [PubMed]
- Rawla, P.; Raj, J.P. Doxycycline-Induced Acute Pancreatitis: A Rare Adverse Event. Gastroenterol. Res. 2017, 10, 244–246. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Naranjo, C.A.; Busto, U.; Sellers, E.M.; Sandor, P.; Ruiz, I.; Roberts, E.A.; Janecek, E.; Domecq, C.; Greenblatt, D.J. A method for estimating the probability of adverse drug reactions. Clin. Pharmacol. Ther. 1981, 30, 239–245. [Google Scholar] [CrossRef] [PubMed]
- Schumock, G.T.; Thornton, J.P. Focusing on the preventability of adverse drug reactions. Hosp. Pharm. 1992, 27, 538. [Google Scholar] [PubMed]
- Hartwig, S.C.; Siegel, J.; Schneider, P.J. Preventability and severity assessment in reporting adverse drug reactions. Am. J. Hosp. Pharm. 1992, 49, 2229–2232. [Google Scholar] [CrossRef] [PubMed]
Day 1 | Day 2 | Day 3 | Day 4 | Day 5 | Day 6 | Day 7 | |
---|---|---|---|---|---|---|---|
Leucocytes (cu mm) | 16.2 | 15.9 | 12.2 | 9.4 | 7.0 | 5.6 | 9.0 |
Erythrocytes (cu mm) | 3.68 | 3.48 | 3.01 | 2.90 | 2.92 | 3.11 | 2.97 |
Hemoglobin (g/dL) | 11.0 | 10.3 | 9.0 | 8.6 | 8.6 | 9.1 | 8.7 |
MCV (fL) | 92.1 | 90.5 | 90.4 | 90.0 | 91.8 | 92.3 | 91.2 |
MCH (pg) | 29.9 | 29.6 | 29.9 | 29.7 | 29.5 | 29.3 | 29.3 |
MCHC (g/dL) | 32.4 | 32.7 | 33.1 | 33.0 | 32.1 | 31.7 | 32.1 |
RDW (%) | 14.9 | 14.3 | 13.9 | 14.2 | 14.3 | 14.2 | 14.1 |
Platelets (K/UL) | 309 | 300 | 253 | 273 | 277 | 238 | 288 |
Immature Gran (%) | 0.2 | 0.3 | 0.2 | 0.4 | 1.4 | 1.3 | 1.7 |
Neutrophils (%) | 85 | 92 | 89 | 85 | 58 | 72 | 65 |
Lymphocytes (%) | 8 | 5 | 6 | 10 | 30 | 20 | 26 |
Monocytes (%) | 7 | 4 | 5 | 5 | 10 | 7 | 8 |
Eosinophils (%) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sodium (mmol/L) | 134 | 138 | 138 | 139 | 141 | 141 | 145 |
Potassium (mmol/L) | 4.6 | 3.6 | 3.1 | 2.6 | 2.6 | 3.8 | 3.5 |
Chloride (mmol/L) | 100 | 102 | 104 | 106 | 110 | 109 | 113 |
Carbon Dioxide (mmol/L) | 20 | 24 | 23 | 24 | 25 | 23 | 25 |
Whole Blood PCO2 (Vol %) | 18.9 | ||||||
Anion Gap | 14.0 | 12.0 | 11.0 | 9.0 | 6.0 | 9.0 | 7.0 |
BUN (mg/dL) | 44 | 38 | 36 | 32 | 31 | 25 | 24 |
Creatinine (mg/dL) | 4.21 | 2.82 | 1.94 | 1.53 | 1.49 | 1.26 | 1.19 |
Est. GFR (African Amer.) | 13 | 21 | 33 | 45 | 46 | 56 | ≥60 |
Glucose (mg/dL) | 144 | 162 | 129 | 121 | 102 | 122 | 125 |
Hemoglobin Alc (%) | 6.1 | ||||||
Lactic Acid (mmol/L) | 1.4 | 0.6 | |||||
Calcium (mg/dL) | 7.9 | 8.1 | 8.0 | 8.1 | 7.8 | 8.0 | 8.2 |
Phosphorous (mg/dL) | 4.1 | 2.6 | 2.2 | 2.2 | |||
Magnesium (mg/dL) | 1.9 | 1.8 | 1.7 | 2.0 | 1.6 | 1.6 | |
Total Bilirubin (mg/dL) | 1.38 | 1.45 | 0.61 | 0.33 | 0.43 | ||
Direct Bilirubin (mg/dL) | <0.10 | <0.10 | 0.12 | ||||
AST (IU/L) | 376 | 205 | 132 | 84 | 63 | ||
ALT (IU/L) | 54 | 49 | 40 | 34 | 33 | ||
Alkaline Phosphatase (IU/L) | 72 | 86 | 57 | 46 | 53 | ||
Creatine Kinase (IU/L) | 61,453 | 43,236 | 18,773 | 9826 | 5451 | 2805 | 1512 |
CK-MB Fraction (ng/mL) | 124.5 | ||||||
Troponin I (ng/mL) | 0.05 | ||||||
BNP (pg/mL) | 120 | ||||||
Total protein (g/dL) | 6.6 | 7.2 | 6.1 | 5.7 | 5.9 | ||
Albumin (g/dL) | 2.7 | 2.6 | 2.4 | 2.3 | 2.2 | 2.4 | |
Globulin (g/dL) | 3.9 | 4.6 | 3.8 | 3.5 | 3.5 | ||
Albumin/Globulin ratio | 0.7 | 0.6 | 0.6 | 0.6 | 0.7 | ||
Triglycerides (mg/dL) | 267 | ||||||
INR | 1.0 | 1.0 | |||||
APTT (seconds) | 32 | 34.2 |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Rawla, P.; Raj, J.P.; George, S.M.; Nathala, P.; Vellipuram, A.R. A Rare Adverse Event of Rhabdomyolysis Caused by Sacubitril/Valsartan. Diseases 2019, 7, 38. https://doi.org/10.3390/diseases7020038
Rawla P, Raj JP, George SM, Nathala P, Vellipuram AR. A Rare Adverse Event of Rhabdomyolysis Caused by Sacubitril/Valsartan. Diseases. 2019; 7(2):38. https://doi.org/10.3390/diseases7020038
Chicago/Turabian StyleRawla, Prashanth, Jeffrey Pradeep Raj, Sajid Melvin George, Pavani Nathala, and Anantha R. Vellipuram. 2019. "A Rare Adverse Event of Rhabdomyolysis Caused by Sacubitril/Valsartan" Diseases 7, no. 2: 38. https://doi.org/10.3390/diseases7020038